Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20759378 | 0.86 | DAO (0.51) | TSHRDAOLMNAMMP13ALDH1A1 | |
| SCHEMBL23482876 | 0.82 | TSHR (0.47) | TSHRDAOLMNAMMP13ALDH1A1 | |
| SCHEMBL20759253 | 0.69 | DAO (0.53) | TSHRDAOLMNAMMP13ALDH1A1 | |
| SCHEMBL8446039 | 0.67 | ALDH1A1 (0.70) | TSHRLMNAALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5794763 | 0.67 | PTGDR2 (0.53) | TSHRDAOLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4291315 | 0.67 | TSHR (0.57) | TSHRDAOLMNAMMP13ALDH1A1 | |
| SCHEMBL3612929 | 0.67 | PLA2G7 (0.58) | CYP3A4 | |
| SCHEMBL18776168 | 0.67 | DAO (0.50) | TSHRDAOLMNAMMP13ALDH1A1 | |
| SCHEMBL18776164 | 0.67 | PTGDR2 (0.51) | TSHRDAOLMNAMMP13ALDH1A1 | |
| SCHEMBL10595385 | 0.67 | DAO (0.50) | TSHRDAOLMNAMMP13ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | VERA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | TSHR 105/4885DAO 1130/4885LMNA 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.